A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease (SHIELD-1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01277666
First received: January 13, 2011
Last updated: January 9, 2014
Last verified: January 2014
  Purpose

This is a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A as compared to placebo over 12 weeks in adult subjects with moderately-to-severely active Crohn's disease. Efficacy will be assessed by proportion of subjects achieving response, defined as a decrease in Crohn's Disease Activity Index (CDAI) score of at least 100 points (clinical response). Clinical remission (CDAI score less than 150 points) will be evaluated as a key secondary endpoint. Safety will be assessed by recording of adverse events, clinical laboratory parameters, vital signs and electrocardiogram (ECG). Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 version 2 (SF-36v2), EQ-5D and Work Productivity and Activity Impairment-CD (WPAI-CD) and receipt of disability.


Condition Intervention Phase
Crohn's Disease
Drug: GSK1605786A
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Proportion of subjects achieving clinical response [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Proportion of subjects achieving clinical response, defined as at least a 100 point decrease from baseline in Crohn's Disease Activity Index (CDAI) score


Secondary Outcome Measures:
  • Proportion of subjects in clinical remission [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Proportion of subjects in clinical remission, defined as a CDAI score of less than 150 points at Week 12

  • Proportion of subjects achieving clinical response at other time points [ Time Frame: 8 and 12 weeks ] [ Designated as safety issue: No ]
    Proportion of subjects achieving clinical response, defined as at least a 100 point decrease from baseline in Crohn's Disease Activity Index (CDAI) score

  • Proportion of subjects in clinical remission at other time points [ Time Frame: 8 and 12 weeks ] [ Designated as safety issue: No ]
    Proportion of subjects in clinical remission defined as a CDAI score of less than 150 points at other time points

  • Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 12

  • Incidence of adverse events or serious adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Incidence of adverse events or serious adverse events by treatment group


Enrollment: 608
Study Start Date: December 2010
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
orally administered
Drug: Placebo
Placebo capsules, administered orally for 12 weeks
Experimental: GSK1605786A 500mg once daily
orally administered
Drug: GSK1605786A
500 mg once daily, administered orally for 12 weeks
Experimental: GSK1605786A 500mg twice daily
orally administered
Drug: GSK1605786A
500 mg twice daily, administered orally for 12 weeks

Detailed Description:

This is a multi-centre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of two oral doses of GSK1605786A (500 mg once daily, 500 mg twice daily) as compared to placebo in the induction of clinical response over a 12-week treatment period in subjects with moderately-to-severely active Crohn's disease. Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of remission.

The study is planned to randomise approximately 600 subjects (200 subjects/group) with active Crohn's disease, diagnosed for at least 4 months with a documented history of disease in the small and/or large intestine, and characterised by a Crohn's Disease Activity Index (CDAI) score between 220 to and 450, inclusive. Subjects must have reported an inadequate response or intolerance to Crohn's disease treatment with corticosteroids or immunosuppressants. Inclusion of subjects who received prior treatment with a biologic anti-tumour necrosis factor (TNF) agent will be limited to approximately 50% of the study population. All subjects are required to have a diagnosis with identification of anatomic location of Crohn's disease, which has been established by visualisation of the gastrointestinal tract within 12 months of screening. Subjects who have not had a visualisation of the gastrointestinal tract within 12 months are required to undergo an endoscopic assessment during the screening period. Subjects will be required to have evidence of current active inflammation at the time of randomisation either by endoscopy or by inflammatory biomarkers [elevated C-reactive protein (CRP) greater than the upper limit of normal (ULN) plus a positive faecal calprotectin test]. Subjects who do not meet the requirements based on inflammatory biomarker test results will be required to qualify based on endoscopic assessment during screening. Subjects will be allowed to participate in the study while continuing on stable doses of agents typically used to treat Crohn's disease. Following the screening period, subjects will be randomised at baseline to receive blinded treatment with one of two doses of GSK1605786A (500 mg once daily or twice daily) or placebo for 12 weeks. Response and remission endpoints, using the CDAI, will be evaluated at Weeks 4, 8 and 12.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects aged 18 years or older
  • Written informed consent
  • Diagnosis of Crohn's disease for greater than 4 months duration with small bowel and/or colonic involvement
  • Confirmation of Crohn's disease established by visualisation of the gastrointestinal tract within the 12 months prior to screening or by screening endoscopy at study entry
  • History of inadequate response and/or intolerance/adverse event leading to discontinuation of either corticosteroids or immunosuppressants
  • Moderately-to-severely active disease characterised by a CDAI score between 220 and 450, inclusive, at Baseline
  • Confirmation of current active Crohn's disease by screening endoscopy or inflammatory biomarkers [elevated C-reactive protein (greater than upper limit of normal) plus positive test for faecal calprotectin] at Screening
  • Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn's disease
  • Demonstrated ability to comply with Crohn's disease symptom recording using the interactive voice response system
  • Females of child-bearing potential must be sexually inactive or commit to consistent and correct use of a contraceptive method of birth control with a failure rate of less than 1% for the duration of this study

Exclusion Criteria:

  • If female: pregnant, has a positive pregnancy test or is breast-feeding
  • Diagnosis of coeliac disease, follow a gluten-free diet to manage symptoms, or positive test for coeliac disease
  • Diagnosis of ulcerative or indeterminate colitis
  • Enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period
  • Bowel surgery, other than appendectomy, within 12 weeks prior to screen and/or has surgery planned or deemed likely for Crohn's disease during the study period
  • Extensive colonic resection, subtotal or total colectomy
  • Presence of ileostomies, colostomies or rectal pouches
  • Known fixed symptomatic stenoses
  • History of more than 3 small bowel resections or diagnosis of short bowel syndrome
  • Chronic use of narcotics for chronic pain defined as daily use of one or more doses of narcotic containing medication
  • Use of prohibited medications, including enteral feeding or elemental diet, within their specified time frames

    1. Biologic use: Use of any biologic (tumour necrosis factor inhibitor or natalizumab) within 8 weeks prior to screening
    2. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to screening
    3. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks prior to screening
    4. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn's disease within 4 weeks prior to screening
    5. Use of rectal treatment with 5-ASA or corticosteroid enemas/suppositories within 2 weeks prior to screening
    6. Use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening
    7. Leukocytapheresis or granulocytapheresis within 2 weeks prior to screening
  • Positive immunoassay for Clostridium difficile
  • Known human immunodeficiency virus (HIV) infection
  • Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening
  • Immunisation with a live vaccine within 4 weeks of screening, with the exception of influenza vaccine
  • Active or latent tuberculosis infection
  • Current sepsis or infections requiring intravenous antibiotic therapy for more than 2 weeks
  • Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of liver disease including non-alcoholic steatohepatitis (NASH)
  • Positive test for Hepatitis B or Hepatitis C antibody at screening
  • Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450 milliseconds
  • Concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study
  • History or evidence of adenomatous colonic polyps that have not been removed
  • History of evidence of colonic mucosal dysplasia
  • Current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or any cancer in situ that has been resected)
  • Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx compound CCX282-B)
  • Medical history of sensitivity to any of the components of GSK1605786A
  • Use of any investigational product within 30 days prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01277666

  Hide Study Locations
Locations
United States, Arizona
GSK Investigational Site
Little Rock, Arizona, United States, 72205
GSK Investigational Site
Tucson, Arizona, United States, 85712
United States, California
GSK Investigational Site
Anaheim, California, United States, 92801
GSK Investigational Site
Los Angeles, California, United States, 90015
GSK Investigational Site
San Diego, California, United States, 92103
GSK Investigational Site
San Francisco, California, United States, 94115
GSK Investigational Site
SanDiego, California, United States, 92103
United States, Colorado
GSK Investigational Site
Lakewood, Colorado, United States, 80215
GSK Investigational Site
Littleton, Colorado, United States, 80120
United States, Connecticut
GSK Investigational Site
Hamden, Connecticut, United States, 06518
United States, Florida
GSK Investigational Site
Jacksonville, Florida, United States, 32256-6004
GSK Investigational Site
Jacksonville, Florida, United States, 32207
GSK Investigational Site
Maitland, Florida, United States, 32751
GSK Investigational Site
Port Orange, Florida, United States, 32127
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30342-5006
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60637
GSK Investigational Site
Oak Lawn, Illinois, United States, 60453
United States, Indiana
GSK Investigational Site
Indianapolis, Indiana, United States, 46237
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40536-0298
United States, Louisiana
GSK Investigational Site
Hammond, Louisiana, United States, 70403
GSK Investigational Site
Monroe, Louisiana, United States, 71201
United States, Maryland
GSK Investigational Site
Chevy Chase, Maryland, United States, 20815
GSK Investigational Site
Towson, Maryland, United States, 21204
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02114
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48109-5048
GSK Investigational Site
Chesterfield, Michigan, United States, 48047
GSK Investigational Site
Troy, Michigan, United States, 48098
United States, Minnesota
GSK Investigational Site
Rochester, Minnesota, United States, 55905
United States, Mississippi
GSK Investigational Site
Jackson, Mississippi, United States, 39202
GSK Investigational Site
Tupelo, Mississippi, United States, 38801
United States, Missouri
GSK Investigational Site
Lee's Summit, Missouri, United States, 64064
United States, New Hampshire
GSK Investigational Site
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
GSK Investigational Site
Egg Harbor Township, New Jersey, United States, 08234
GSK Investigational Site
Voorhees, New Jersey, United States, 08043
United States, New York
GSK Investigational Site
Great Neck, New York, United States, 11021
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
GSK Investigational Site
Durham, North Carolina, United States, 27710
GSK Investigational Site
Raleigh, North Carolina, United States, 27612
United States, Ohio
GSK Investigational Site
Columbus, Ohio, United States, 43215
United States, Oklahoma
GSK Investigational Site
Tulsa, Oklahoma, United States, 74135
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97225
United States, Tennessee
GSK Investigational Site
Germantown, Tennessee, United States, 38138
GSK Investigational Site
Nashville, Tennessee, United States, 37212-1610
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78745
GSK Investigational Site
Houston, Texas, United States, 77034-0550
GSK Investigational Site
Pasadena, Texas, United States, 77505
GSK Investigational Site
San Antonio, Texas, United States, 78229
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98101
GSK Investigational Site
Seattle, Washington, United States, 98195
Australia, New South Wales
GSK Investigational Site
Bankstown, New South Wales, Australia, 2200
Australia, Queensland
GSK Investigational Site
Hersten, Queensland, Australia, 4029
Australia, South Australia
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
GSK Investigational Site
Kurralta Park, South Australia, Australia, 5037
Australia, Victoria
GSK Investigational Site
Fitzroy, Victoria, Australia, 3065
GSK Investigational Site
Prahran, Victoria, Australia, 3181
Australia, Western Australia
GSK Investigational Site
Fremantle, Western Australia, Australia, 6160
Austria
GSK Investigational Site
Hall in Tirol, Austria, 6060
GSK Investigational Site
Linz, Austria, A-4021
GSK Investigational Site
Wien, Austria, 1050
GSK Investigational Site
Wien, Austria, 1090
Belgium
GSK Investigational Site
Bonheiden, Belgium, 2820
GSK Investigational Site
Brussels, Belgium, 1000
GSK Investigational Site
Brussels, Belgium, 1200
GSK Investigational Site
Edegem, Belgium, 2650
GSK Investigational Site
Gent, Belgium, 9000
GSK Investigational Site
Kortrijk, Belgium, 8500
GSK Investigational Site
Leuven, Belgium, 3000
GSK Investigational Site
Roeselare, Belgium, 8800
Canada, Alberta
GSK Investigational Site
Calgary, Alberta, Canada, T2N 4Z6
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 2X8
Canada, British Columbia
GSK Investigational Site
Abbotsford, British Columbia, Canada, V2S 3N5
GSK Investigational Site
Vancouver, British Columbia, Canada, V6Z 2K5
GSK Investigational Site
Victoria, British Columbia, Canada, V8V 3M9
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R3A 1R9
Canada, Nova Scotia
GSK Investigational Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 4A6
GSK Investigational Site
Hamilton, Ontario, Canada, L8S 4K1
GSK Investigational Site
Kingston, Ontario, Canada, K7L 5G2
GSK Investigational Site
London, Ontario, Canada, N6A 5A5
GSK Investigational Site
London, Ontario, Canada, N6A 5W9
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 1A2
GSK Investigational Site
Richmond Hill, Ontario, Canada, L4B 3P8
GSK Investigational Site
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
GSK Investigational Site
Levis, Quebec, Canada, G6V 3Z1
GSK Investigational Site
Montreal, Quebec, Canada, H3T 1E2
GSK Investigational Site
Montreal, Quebec, Canada, H3A 1A1
Canada
GSK Investigational Site
Quebec, Canada, G1S 4L8
GSK Investigational Site
Quebec, Canada, G3K 2P8
Czech Republic
GSK Investigational Site
Brno, Czech Republic, 625 00
GSK Investigational Site
Hradec Králové, Czech Republic, 500 12
GSK Investigational Site
Olomouc, Czech Republic, 77520
GSK Investigational Site
Ostrava - Vitkovice, Czech Republic, 70384
GSK Investigational Site
Praha 10, Czech Republic, 100 34
GSK Investigational Site
Praha 4, Czech Republic, 140 21
GSK Investigational Site
Praha 7, Czech Republic, 17004
GSK Investigational Site
Praha 9, Czech Republic, 190 00
Denmark
GSK Investigational Site
Aalborg, Denmark, 9000
GSK Investigational Site
Aarhus, Denmark, 8000
GSK Investigational Site
Herlev, Denmark, 2730
GSK Investigational Site
Hvidovre, Denmark, 2650
GSK Investigational Site
Odense, Denmark, 5000
France
GSK Investigational Site
Amiens cedex 1, France, 80054
GSK Investigational Site
Clichy cedex, France, 92118
GSK Investigational Site
Lille cedex, France, 59037
GSK Investigational Site
Nantes cedex 1, France, 44093
GSK Investigational Site
Nice cedex 3, France, 06202
GSK Investigational Site
Paris cedex 10, France, 75475
GSK Investigational Site
Pessac cedex, France, 33604
GSK Investigational Site
Saint-Priest en Jarez, France, 42270
GSK Investigational Site
Vandoeuvre Les Nancy, France, 54511
Germany
GSK Investigational Site
Freiburg, Baden-Wuerttemberg, Germany, 79106
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89081
GSK Investigational Site
Frankfurt am Main, Hessen, Germany, 60590
GSK Investigational Site
Braunschweig, Niedersachsen, Germany, 38126
GSK Investigational Site
Brinkum/Stuhr, Niedersachsen, Germany, 28816
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50937
GSK Investigational Site
Minden, Nordrhein-Westfalen, Germany, 32423
GSK Investigational Site
Muenster, Nordrhein-Westfalen, Germany, 48159
GSK Investigational Site
Muenster, Nordrhein-Westfalen, Germany, 48149
GSK Investigational Site
Ludwigshafen, Rheinland-Pfalz, Germany, 67067
GSK Investigational Site
Dessau, Sachsen-Anhalt, Germany, 06847
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06120
GSK Investigational Site
Jena, Thueringen, Germany, 07747
GSK Investigational Site
Berlin, Germany, 10117
GSK Investigational Site
Berlin, Germany, 12157
GSK Investigational Site
Berlin, Germany, 13353
GSK Investigational Site
Hamburg, Germany, 22559
GSK Investigational Site
Hamburg, Germany, 20148
Hungary
GSK Investigational Site
Bekescsaba, Hungary, 5600
GSK Investigational Site
Budapest, Hungary, 1088
GSK Investigational Site
Szekszárd, Hungary, 7100
Israel
GSK Investigational Site
Haifa, Israel, 31096
GSK Investigational Site
Holon, Israel, 58100
GSK Investigational Site
Jerusalem, Israel, 91031
GSK Investigational Site
Jerusalem, Israel, 91120
GSK Investigational Site
Kfar Saba, Israel, 44281
GSK Investigational Site
Petach Tikva, Israel, 49100
GSK Investigational Site
Tel Aviv, Israel, 64239
Italy
GSK Investigational Site
Palermo, Sicilia, Italy, 90127
GSK Investigational Site
Genova, Italy, 16132
GSK Investigational Site
Modena, Italy, 41100
GSK Investigational Site
Roma, Italy, 00152
GSK Investigational Site
Roma, Italy, 00168
Japan
GSK Investigational Site
Aichi, Japan, 466-8560
GSK Investigational Site
Aichi, Japan, 460-0012
GSK Investigational Site
Chiba, Japan, 285-8741
GSK Investigational Site
Fukuoka, Japan, 818-8502
GSK Investigational Site
Fukuoka, Japan, 812-8582
GSK Investigational Site
Hokkaido, Japan, 060-0033
GSK Investigational Site
Hyogo, Japan, 663-8501
GSK Investigational Site
Kagoshima, Japan, 892-8512
GSK Investigational Site
Kagoshima, Japan, 892-0846
GSK Investigational Site
Miyagi, Japan, 981-3213
GSK Investigational Site
Osaka, Japan, 530-0011
GSK Investigational Site
Osaka, Japan, 545-8586
GSK Investigational Site
Tokyo, Japan, 169-0073
GSK Investigational Site
Tokyo, Japan, 113-8519
GSK Investigational Site
Tokyo, Japan, 160-8582
Korea, Republic of
GSK Investigational Site
Daegu, Korea, Republic of, 705-717
GSK Investigational Site
Pusan, Korea, Republic of, 602-739
GSK Investigational Site
Seoul, Korea, Republic of, 130-702
GSK Investigational Site
Seoul, Korea, Republic of, 120-752
GSK Investigational Site
Seoul, Korea, Republic of, 135-230
GSK Investigational Site
Wonju, Korea, Republic of, 220701
Netherlands
GSK Investigational Site
Almere, Netherlands, 1315 RA
GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
GSK Investigational Site
Amsterdam, Netherlands, 1091 AC
GSK Investigational Site
EDE, Netherlands, 6716 RP
GSK Investigational Site
Heerlen, Netherlands, 6419 PC
GSK Investigational Site
Rotterdam, Netherlands, 3015 CE
New Zealand
GSK Investigational Site
Auckland, New Zealand, 1148
GSK Investigational Site
Dunedin, New Zealand, 9054
GSK Investigational Site
Hamilton, New Zealand, 3204
GSK Investigational Site
Lower Hutt, New Zealand, 6007
GSK Investigational Site
Otahuhu, New Zealand, 1640
GSK Investigational Site
Tauranga., New Zealand, 3143
Norway
GSK Investigational Site
Bodø, Norway, 8005
GSK Investigational Site
Oslo, Norway, N-0456
GSK Investigational Site
Tromsø, Norway, 9038
GSK Investigational Site
Trondheim, Norway, 7030
GSK Investigational Site
Tønsberg, Norway, 3116
GSK Investigational Site
Ålesund, Norway, 6017
Poland
GSK Investigational Site
Bydgoszcz, Poland, 85-168
GSK Investigational Site
Bydgoszcz, Poland, 85-681
GSK Investigational Site
Elblag, Poland, 82-300
GSK Investigational Site
Lublin, Poland, 20-607
GSK Investigational Site
Sopot, Poland, 81-756
GSK Investigational Site
Torun, Poland, 87-100
GSK Investigational Site
Wroclaw, Poland, 53-333
Slovakia
GSK Investigational Site
Bratislava, Slovakia, 851 01
GSK Investigational Site
Bratislava, Slovakia, 831 04
GSK Investigational Site
Bratislava, Slovakia, 851 07
GSK Investigational Site
Nitra, Slovakia, 949 01
GSK Investigational Site
Nove Mesto nad Vahom, Slovakia, 915 01
GSK Investigational Site
Presov, Slovakia, 080 01
GSK Investigational Site
Trnava, Slovakia, 917 02
South Africa
GSK Investigational Site
Bellville, South Africa, 7530
GSK Investigational Site
Claremont, South Africa, 7708
GSK Investigational Site
Observatory, South Africa, 7925
GSK Investigational Site
Parktown, South Africa, 2192
Spain
GSK Investigational Site
Badalona, Spain, 08916
GSK Investigational Site
Elche, Spain, 03293
GSK Investigational Site
Galdakao/Vizcaya, Spain, 48960
GSK Investigational Site
Madrid, Spain, 28046
GSK Investigational Site
Sabadell (Barcelona), Spain, 08208
Sweden
GSK Investigational Site
Göteborg, Sweden, SE-416 85
GSK Investigational Site
Lund, Sweden, SE-221 85
GSK Investigational Site
Stockholm, Sweden, SE-171 76
GSK Investigational Site
Stockholm, Sweden, SE-182 88
GSK Investigational Site
Umeå, Sweden, SE-901 85
United Kingdom
GSK Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ
GSK Investigational Site
Birmingham, United Kingdom, B9 5SS
GSK Investigational Site
Bristol, United Kingdom, BS2 8HW
GSK Investigational Site
Edinburgh, United Kingdom, EH4 2XU
GSK Investigational Site
Manchester, United Kingdom, M13 9WL
GSK Investigational Site
Newcastle-upon-Tyne, United Kingdom, NE1 4LP
GSK Investigational Site
Nottingham, United Kingdom, NG7 2UH
GSK Investigational Site
Oxford, United Kingdom, OX3 9DU
GSK Investigational Site
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01277666     History of Changes
Other Study ID Numbers: 114151
Study First Received: January 13, 2011
Last Updated: January 9, 2014
Health Authority: European Union: European Medicines Agency
Australia: Human Research Ethics Committee
Belgium: Federal Agency for Medicines and Health Products, FAMHP
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Japan: Pharmaceutical and Medical Device Agency
United States: Food and Drug Administration
Norway: Norwegian Medicines Agency
Denmark: Danish Medicines Agency
Australia: Department of Health and Ageing Therapeutic Goods Administration
Canada: Health Canada

Keywords provided by GlaxoSmithKline:
Crohn's disease
capsule
GSK1605786A
quality of life
inflammatory bowel disease
oral therapy

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on July 23, 2014